AKT1 and fibrosarcoma: • Host targeting drug, nitroxoline [76]: Although its mechanism of action is not known, nitroxoline inhibits the phosphoinositide 3‐kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway and stimulates the fibrosarcoma/mitogen‐activated protein kinase/extracellular signal‐regulated kinase (RAF/MEK/ERK) signaling pathway.